利妥昔单抗治疗自身免疫性疱病：最新研究，新见解。
Rituximab for autoimmune blistering diseases: recent studies, new insights.
机构信息
Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
G Ital Dermatol Venereol. 2012 Jun;147(3):269-76.
Abstract
Rituximab, an anti-CD20 monoclonal antibody, has been successfully used off-label for treatment of autoimmune blistering diseases. We discuss rituximab mechanisms of action, host factors that may affect response to rituximab, and the efficacy and safety of rituximab in autoimmune blistering diseases, incorporating recent data on the use of rituximab in other autoimmune disease patients.
摘要
利妥昔单抗，一种抗 CD20 单克隆抗体，已被成功地用于治疗自身免疫性水疱病的适应证外治疗。我们讨论了利妥昔单抗的作用机制、可能影响其疗效的宿主因素，以及利妥昔单抗在自身免疫性水疱病中的疗效和安全性，并纳入了利妥昔单抗在其他自身免疫性疾病患者中应用的最新数据。
相似文献
1
Rituximab for autoimmune blistering diseases: recent studies, new insights.利妥昔单抗治疗自身免疫性疱病：最新研究，新见解。
G Ital Dermatol Venereol. 2012 Jun;147(3):269-76.
2
Rituximab and its use in autoimmune bullous disorders.利妥昔单抗及其在自身免疫性大疱性疾病中的应用。
Dermatol Clin. 2011 Oct;29(4):571-5. doi: 10.1016/j.det.2011.06.023.
3
Rituximab in treatment-resistant autoimmune blistering skin disorders.利妥昔单抗治疗难治性自身免疫性水疱性皮肤病
Clin Rev Allergy Immunol. 2008 Feb;34(1):56-64. doi: 10.1007/s12016-007-8021-6.
4
Rituximab in refractory autoimmune bullous diseases.利妥昔单抗治疗难治性自身免疫性大疱性疾病
Clin Exp Dermatol. 2006 Jul;31(4):503-8. doi: 10.1111/j.1365-2230.2006.02151.x.
5
[Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].利妥昔单抗（抗CD20）用于治疗自身免疫性大疱性疾病
Hautarzt. 2007 Feb;58(2):115-6, 118-21. doi: 10.1007/s00105-007-1284-2.
6
Current treatment of autoimmune blistering diseases.自身免疫性水疱病的当前治疗方法。
Curr Drug Discov Technol. 2009 Dec;6(4):270-80. doi: 10.2174/157016309789869065.
7
Rituximab and its use in autoimmune bullous disorders.利妥昔单抗及其在自身免疫性大疱性疾病中的应用。
Immunol Allergy Clin North Am. 2012 May;32(2):331-7, viii. doi: 10.1016/j.iac.2012.04.013. Epub 2012 Apr 18.
8
Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions.利妥昔单抗超低剂量方案治疗自身免疫性水疱性皮肤病
Front Immunol. 2018 Apr 18;9:810. doi: 10.3389/fimmu.2018.00810. eCollection 2018.
9
[Autoimmune blistering skin diseases: diagnostic and therapeutic approach].[自身免疫性水疱性皮肤病：诊断与治疗方法]
Dtsch Med Wochenschr. 2014 Jul;139(28-29):1473-7. doi: 10.1055/s-0034-1370151. Epub 2014 Jul 1.
10
Rituximab for the treatment of autoimmune subepidermal blistering diseases.利妥昔单抗治疗自身免疫性表皮下大疱性疾病。
Dermatol Ther. 2018 Sep;31(5):e12687. doi: 10.1111/dth.12687. Epub 2018 Sep 11.
引用本文的文献
1
Mechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases.用于治疗自身免疫性大疱性疾病的利妥昔单抗耐药机制。
Life (Basel). 2024 Sep 25;14(10):1223. doi: 10.3390/life14101223.
2
Immunosuppressive Cyclotides: A Promising Approach for Treating Autoimmune Diseases.免疫抑制环肽：治疗自身免疫性疾病的一种有前途的方法。
Protein J. 2024 Apr;43(2):159-170. doi: 10.1007/s10930-024-10188-y. Epub 2024 Mar 15.
3
The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature.静脉注射免疫球蛋白在黏膜类天疱疮治疗中的作用：文献综述
J Res Med Sci. 2016 Jun 14;21:37. doi: 10.4103/1735-1995.183992. eCollection 2016.
4
[Pemphigus. Model disease for targeted therapy].[天疱疮。靶向治疗的模型疾病]
Hautarzt. 2015 Aug;66(8):574-82. doi: 10.1007/s00105-015-3656-3.
5
Diabetes tolerogenic vaccines targeting antigen-specific inflammation.针对抗原特异性炎症的糖尿病耐受性疫苗。
Hum Vaccin Immunother. 2015;11(2):522-30. doi: 10.1080/21645515.2014.1004024.
6
Immunosuppressive peptides and their therapeutic applications.免疫抑制肽及其治疗应用。
Drug Discov Today. 2014 May;19(5):645-53. doi: 10.1016/j.drudis.2013.12.002. Epub 2013 Dec 11.
本文引用的文献
1
Rituximab: Mechanism of action and resistance.利妥昔单抗：作用机制与耐药性。
Semin Oncol. 2002 Feb;29(1S2):2-9. doi: 10.1053/sonc.2002.30156.
2
Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus.一名天疱疮患者体内存在针对利妥昔单抗的抑制性人抗嵌合抗体。
J Allergy Clin Immunol. 2012 Sep;130(3):800-3. doi: 10.1016/j.jaci.2012.03.022. Epub 2012 Apr 26.
3
Efficacy and safety of rituximab treatment in Indian pemphigus patients.利妥昔单抗治疗印度天疱疮患者的疗效和安全性。
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e17-23. doi: 10.1111/j.1468-3083.2011.04391.x. Epub 2011 Dec 17.
4
Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.大疱性类天疱疮的定义和结局评估：国际专家组的建议。
J Am Acad Dermatol. 2012 Mar;66(3):479-85. doi: 10.1016/j.jaad.2011.06.032. Epub 2011 Nov 5.
5
Low-dose rituximab is effective in pemphigus.小剂量利妥昔单抗治疗天疱疮有效。
Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365-2133.2011.10663.x. Epub 2012 Jan 9.
6
Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.利妥昔单抗治疗寻常型天疱疮的相关性：对现有数据的分析及其观察到的反应的免疫学基础。
Expert Rev Clin Immunol. 2011 Jul;7(4):529-41. doi: 10.1586/eci.11.22.
7
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.骨髓基质细胞可保护淋巴瘤 B 细胞免受利妥昔单抗诱导的凋亡，而用那他珠单抗靶向整合素 α-4-β-1（VLA-4）则可克服这种耐药性。
Br J Haematol. 2011 Oct;155(1):53-64. doi: 10.1111/j.1365-2141.2011.08794.x. Epub 2011 Jul 12.
8
Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.利妥昔单抗治疗难治性天疱疮和类天疱疮：17 例病例系列。
J Am Acad Dermatol. 2011 Sep;65(3):552-558. doi: 10.1016/j.jaad.2010.07.032.
9
Pathogenesis of epidermolysis bullosa acquisita.获得性大疱性表皮松解症的发病机制。
Dermatol Clin. 2011 Jul;29(3):493-501, xi. doi: 10.1016/j.det.2011.03.003.
10
Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients.不同剂量利妥昔单抗治疗天疱疮的临床疗效：27 例回顾性研究。
Br J Dermatol. 2011 Sep;165(3):646-51. doi: 10.1111/j.1365-2133.2011.10411.x.
Zotero 插件